why choose us

First received: February 01, 2023

Clinical Trial: Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Study Status: Completed

Recruit Status: RECRUITING

Condition: Colon Cancer

Study Type: INTERVENTIONAL


Official Title: Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

Brief Summary: To find the recommended dose of MRTX849 that can be given in combination with cetuximab and irinotecan to patients with colorectal cancer that have a mutation (genetic change) called KRAS G12C.

Read more